EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.14.99.1 | 5,8,11,14-Eicosatetraynoic acid | - |
Oryctolagus cuniculus | |
1.14.99.1 | Acetylsalicylic acid | irreversible inhibitor | Oryctolagus cuniculus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.14.99.1 | Oryctolagus cuniculus | - |
isozymes PHS-1 and PHS-2 | - |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.14.99.1 | embryo | - |
Oryctolagus cuniculus | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.14.99.1 | PHS | - |
Oryctolagus cuniculus |
1.14.99.1 | prostaglandin H synthase | - |
Oryctolagus cuniculus |
EC Number | General Information | Comment | Organism |
---|---|---|---|
1.14.99.1 | additional information | PHS is involved in the mechanism of thalidomide to cause increased embryonic DNA oxidation measured as 8-oxoguanine leading to embryopathies, phenotype, overview. A prostaglandin H synthase-dependent, reactive oxygen species-mediated mechanism. Thalidomide teratogenicity was blocked by maternal pretreatment with acetylsalicylic acid, an irreversible inhibitor of prostaglandin H synthase | Oryctolagus cuniculus |